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L E T T E R
Sickle cell disease and COVID-19: Atypical presentations and
favorable outcomes
COVID-19 pandemic has already claimed several lives. Individualswith
underlyinghealth conditions including sickle cell disease (SCD) are con-
sidered to be at higher risk of complications from the severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2). Here, we report our
experiencewith three patients with severe SS SCD, all originating from
Congo that contracted COVID-19 infection (Table 1). All three devel-
oped only mild symptoms with few respiratory symptoms at presenta-
tion that did not require intensive care unit admission. All threeof them
initially received automated red cell exchange transfusion (ET) accord-
ing to the current recommendations [1].
Our first patient is a young woman with SS Bantu phenotype,
aged 23, who came for a regular visit for planning her next ET. Her
usual treatment regimen was ET using six red blood cell units (RBCU)
every 5 weeks with a target HbS fraction of 50% for previous recur-
rent painful vaso-occlusive crises (VOC). She was also receiving treat-
ment with hydroxycarbamide but with poor compliance, folic acid, and
aspirin tomaintainher arteriovenous fistula. Shementionedhavinghad
cough 2 weeks prior to the current visit and a fever of 38◦C treated by
her general practitioner with amoxicillin for 7 days with good response
except for some mild VOC symptoms. She was screened positive for
COVID-19 by PCR nasopharyngeal swab. Computed tomography (CT)
of her thorax showed unilateral ground glass features suggestive of
COVID-19. She was hospitalized for 48 h. ET was performed the fol-
lowing day and also treated with clarithromycin for 7 days with very
good outcome and no need for re-hospitalization.
The second patient is a 44 year-old man with SS SCD with very few
past episodes ofVOCbutwith history of hypertension and severe renal
insufficiency with significant proteinuria. He had basal hemoglobin
(Hb) around 5.4 g/dL despite weekly erythropoietin (EPO) adminis-
tration and poor compliance with low-dose hydroxyurea and ACE
inhibitors. He came for a routine visit with a symptomatic leg ulcer for
2weeks,whichhe linked tohydroxyurea that hehadbeenmore compli-
antwith at a low dose of 500mg daily. He alsomentioned coughing and
slight dyspnea for about a week. He was tested SARS-CoV-2 positive
by PCR on the nasopharyngeal swab. His chest CT scan showed typical
features of COVID infection. After a transfusion of two RBCUs, an iso-
volumic ETwith anHbS target fractionof 20%, anda targetHbof 7 g/dL
was also performed. He also received hydroxychloroquine while an in-
patient according to our local practice. About 10 days after admission,
he developed abdominal pain with ascites and hepatic enlargement.
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At this time, quite surprisingly his Hb level rose up to 10 g/dL, with
extreme reticulocytosis. A second ET was performed and the weekly
EPO injection was with-held. He improved well with healing of his leg
ulcer and rapid clearance of his lung lesion but with no impact on his
renal function (creatinine clearanceunder20mL/min/1.73š). At day30,
he had normal vital signs; the PCR on the swab was negative, COVID
serology still positive. CRP returned to normal, and a repeat CT thorax
showed early changes of fibrosis.
The third patient is a 23-year-old lady with SS SCD admitted for
VOC that developed after repeated bouts of vomiting and developed
acute renal insufficiency.Her chestCT revealed a pneumomediastinum
with no underlying lung lesions(Figure 1) . Following the description of
a similar case in the literature [2], she was screened for COVID-19 by
nasal swab and was found to be positive. There were no abnormalities
of the gastrointestinal tract on endoscopy. She was receiving treat-
ment with hydroxycarbamide, folic acid, vitamin D, and deferasirox.
She received ET and was also treated with ceftriaxone and metronida-
zole to prevent mediastinitis. While the control chest CT scanner on
day 9 showed no more pneumomediastinum and no lung embolism or
infiltrate, she developed a focal non occlusive deep venous thrombosis
(DVT) on femoralis comunis vena at the site of catheter insertion at
day 11 (despite thrombo-prophylaxis with low dose enoxaparin). A
cardiac echography was performed the same day and did not show any
indirect sign of lung embolism, an angioscanner performed a few days
later did not show any pulmonale embolism. She was anticoagulated
with therapeutic low molecular weight heparin and sent home on day
16. She came back 1 week later for severe VOC symptoms. Her chest
scan then showed bi-basal lung lesions atypical for COVID, which
could also be interpreted as a delayed hemolytic transfusion reaction
(DHTR). SARS-CoV-2 test was still positive on nasal swab. Coombs test
was negative but since she had been recently transfused, evaluation
for the risk of DHTR was made according to the proposed model by
the team of Habibi et al [3] and considered intermediate. We decided
not to transfuse nor perform a second ET and rather observed her
carefully. She had a favorable clinical course, although her Hb level
dropped significantly to 5.6 g/dL. Her Hemoglobin spontaneously
slowly recovered without any erythropoietin or rituximab adjunction.
She received no specific COVID-19 treatment except oxygen support
and antibiotherapy with ceftriaxone with oxygen dependency initially
but improvedwell andwas discharged at day 51.
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TABLE 1 Characteristics of the patients
Patient 1 2 3
Age 23 44 23
Sex Female Male Female
Blood group A Positif ccee Kell négatif AB Positif ccee Kell négatif A Négatif ccee Kell négatif
Hemoglobinopathy SS (Bantu phenotype) SS (Bantu phenotype) and Alpha
Thalassemia trait
SS (Bantu phenotype) and G6PD deficiency
Origin Congo Congo Congo
HTA No Yes No
Obesity No No No
Hydroxyurea Yes lowCompliance Yes Yes
Aspirin Yes No No
Regular exchange therapy Yes No No
Deferasirox No No Yes
COVID -19 diagnosis PCR PCR PCR
Lung lesion at entry Unilateral ground glass Mild typical COVID lesion Pneumomediastin ; no lung lesion
Length of PCR positivity > 30 days
Respiratory symptoms Cough Cough None
Others symptoms Abdominal pain, weight loss Leg ulcer Dehydration after vomiting
Deep venous thrombosis No No localized DVT catheter site 11 days after ET
Renal insufficiency No Yes but already basal Acute and reversible
Intensive care No No No
Exchange therapy Regular, one during COVID 2 during COVID 1 ( suspected DHTR)
Hydroxychloroquin No 400mg x 2/d then
200mg x2/d 5 d
No
Anticoagulants No No (renal insufficiency) enoxaparin 40mg/d prophylactic, then after DVT
tinzaparin 175U/kg
There are now more data in the literature of SCD patients encoun-
tering COVID-19 infections [4–6]. In the English case reports as in
the largest registry to date, the French registry published recently,
the authors underline that SARS-COV2 does not seem to carry an
increased risk of mortality or morbidity in patients with SCD [4,6].
Age was retained as the main risk factor, and patients with the most
severe outcome were surprisingly observed in patients with SC phe-
notype. In our patients, homozygous SS of the most severe Bantu
phenotype, there were no features of acute chest syndrome despite
COVID-19 infection and even a pneumomediastinum in the third
case.
Based on our short case series, we hypothesized the milder clini-
cal presentation of COVID-19 may be linked to the sickled red cell. A
recent report of the WHO underlines that globally Africa is the least
affected with 1.5% of the world’s reported cases of COVID-19 and
0.1% of the world’s death [7]. On the contrary, world map reparti-
tion of hemoglobinopathies and malaria coincide strongly and WHO
estimates that SCD accounts for up to 15% of mortality in Africa,
where most children do not live over the age of 5 years despite excit-
ing new therapeutic possibilities, however not reaching low income
countries [8]. SCD is due to the modification of a single gene on
chromosome 11, which will lead to a loss of membrane deformabil-
ity of the red blood cell, increased RBC-endothelial cell adhesion,
and development of severe systemic vasculopathy. Endothelial activa-
tion plays a central role in the pathophysiology of vaso-occlusion in
SCD along with a now well acknowledged discharge of microparticles
and release of free hemoglobin [9]. Resistance to malaria of patients
carriers of hemoglobinopathies is a complex phenomenon that has
been linked to adaptation of the host response with parasite seques-
tration and cytoadherence to endothelium [10]. The Koehl group
has recently demonstrated by proteomic analysis that neutrophils in
SCD present an unexpected activation of the interferon-α signaling
pathway [11]. Gaertner and Massberg, in their fascinating review on
immunothrombosis, have also advocated that fibrin forms a trap for
invading pathogens and provides the recruitment of immune effector
cells, a now recognized important defence mechanism in innate immu-
nity while uncontrolled immunothrombosis can lead to disseminated
intravascular coagulation [12]. Morera et al have also shown that ery-
throcytes may have a direct role in the immune response [13] while
Dragovich et al recently demonstrated that cell membrane tension and
stiffness might be the dominant defense against Ebola attachment to
host cell in an atomic forcemodel [14]. Could this play a role here in the
adaptationof the immune responseof SCDpatients toCOVID-19?This
still remains to be further evaluated.
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F IGURE 1 CT scanner showing Spontaneous pneumomediastin
with no underlying lung lesion in patient 3 with severe SS sickle cell
disease at presentation
Our patients were treated for their disease with various chronic
medicationswith a relative compliance: all three receivedhydroxyurea,
folic acid, and vitamin D. Patient 1 was treated by chronic ET, whereas
patient 3 also received deferasirox until admission. Hydroxyurea has
been used for more than 10 years in Europe and has changed the
prognostic of sickle cell patients [15]. Hydroxyurea not only augments
both HbF level and red blood cell deformability but also maintains the
endothelium and Neutrophils Extracellular Traps (NET) equilibrium,
and impacts the release ofmicroparticles [16]. In the French registry, in
patients with the worst outcome, age was mentioned as the most rel-
evant risk factor but the mean dosage of Hydroxurea in those patients
was also low and could have been a confounding factor [6]. Vitamin D
deficiency may be correlated with severity of SARS-Cov 2 infections
especially in ethnicminorities [17], however the vitaminD levels of our
patients were, despite supplementation, still remarkably low, and thus
likely have not played any protective role here.
This short case series shows that the evolution of sickle cell patients
with COVID-19 can be misleading. Our third patient presented ini-
tially no lung lesions despite a severe pneumomediastin but after het
exchange transfusion developed abnormality on CT scanner compat-
ible with COVID-19, in fact related to delayed hemolytic transfusion
reaction. We encourage clinicians to treat SCD patients with COVID-
19 infection on a case by case basis and not consider them for trans-
fusion invariably but if transfused, to always consider and score for
the risk of DHTR [3]. We are hopeful that a careful analysis of the
large registries of COVID-19 among patientswith hemoglobinopathies
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